Labcorp (LH) official guidance

We continue to expect capital expenditures to be approximately 4% of revenue.

We continue to expect capital expenditures to be approximately 4% revenue as we are investing in the new strategic facility to support long-term growth in our central lab services operations.

We expect the 2026 capital expenditures to be approximately 4% of revenue, higher relative to prior year, as we begin investing in a new strategic facility to support long-term growth in our Central Labs service operations.

We continue to expect our full-year adjusted tax rate to be approximately 23%.

Despite this benefit, we continue to expect our full year adjusted tax rate to be around 23%.

We expect our adjusted tax rate for 2026 to be approximately 23%, and we expect net interest expense of approximately $230 million.

| Adjusted EPS | $18.10 | $18.55 | $18.30 | $18.70 |

| Adjusted EPS | $18.10 | $18.55 |

Our adjusted EPS guidance range is $18.10-$18.55, with an implied growth at the midpoint of more than 11%.

| Adjusted EPS | $17.70 | $18.35 | $18.10 | $18.55 |

Our adjusted EPS guidance range is $17.70-$18.35, with an implied growth rate at the midpoint of approximately 10%.

| Adjusted EPS | $17.55 | $18.25 | $17.70 | $18.35 |

Our guidance range for adjusted EPS is $17.65-$18.25, with an implied growth rate at the midpoint of approximately 9% and includes an impact from adverse weather year-to-date.

◦Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%

| Free Cash Flow | $1,240 | $1,360 | $1,240 | $1,360 |

| Free Cash Flow | $1,240 | $1,360 |

We continue to expect free cash flow in the range of $1.24 billion to $1.36 billion for full year 2026.

| Free Cash Flow | $1,240 | $1,360 | $1,240 | $1,360 |

Our free cash flow guidance range remains $1.24 billion-$1.36 billion, weighted towards the second half of the year.

| Free Cash Flow | $1.24 | $1.36 | $1.24 | $1.36 |

Our free cash flow guidance range is $1.24 billion-$1.36 billion.

◦Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%

We continue to expect enterprise margin expansion, with margins improving in both Diagnostics and BLS in 2026 versus 2025.

We continue to expect enterprise margin expansion, with margins improving in both diagnostics and BLS in 2025 versus 2025.

For the full year, on an organic constant currency basis, we continue to expect Central Lab's revenue to grow in the mid-single digits.

For the full year, on an organic constant currency basis, we continue to expect the central labs revenue to grow in the mid-single digits, and for early development revenue to be relatively flat, with the second half being stronger than the first half.

For the full year, we expect Central Labs to grow mid-single digits, organic constant currency, with Early Development relatively flat, improving throughout the year.

| Growth (3) | 5.5% | 6.5% |

BLS segment revenue is expected to grow 5.5%-6.5%.

We expect BLS Segment revenue to grow 3.8%-5.4%.

We expect BLS revenue to grow 3%-5% versus prior year.

| Biopharma Laboratory Services (4) | $3.10 | 3.0% | 5.0% |

| Growth (3) | 5.4% | 6.3% |

Enterprise revenue is expected to grow 5.4%-6.3%, which represents a 30 basis point increase at the midpoint.

Looking at revenue, we expect enterprise revenue to grow 5%-6.1%.

Beginning with the enterprise, we expect revenue to grow 4.7%-6% compared to prior year.

| Biopharma Laboratory Services (4) | $3,269 | $3,300 |

| Biopharma Laboratory Services (4) | $3,216 | $3,266 | $3,269 | $3,300 |

| Biopharma Laboratory Services (4) | $3.19 | $3.25 | $3.22 | $3.27 |

| Diagnostics Laboratories | $11,450 | $11,532 |

| Diagnostics Laboratories | $11,431 | $11,518 | $11,450 | $11,532 |

| Diagnostics Laboratories | $11.42 | $11.53 | $11.43 | $11.52 |

| Labcorp Enterprise (1) (2) | $14,710 | $14,827 |

| Labcorp Enterprise (1)(2) | $14,649 | $14,803 | $14,710 | $14,827 |

| | Previous | | Updated | | | | 2026 Guidance | | 2026 Guidance | | | | Low | High | Low | High | | Revenue | | | | | | Labcorp Enterprise (1)(2) | $14.61 | $14.79 | $14.65 | $14.80 |

◦Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%

Diagnostics segment revenue is expected to grow 5.3%-6%.

We expect Diagnostics Segment revenue to grow 5.1%-5.9%.

We expect diagnostics revenue to be up 5%-6% compared to 2025.

| Diagnostics Laboratories (3) | $10.88 | 5.0% | 6.0% |